1037253-14-7

Basic information

• Product Name: 5-broMo-3-ethylpyridin-2-aMine
• Synonyms: 5-broMo-3-ethylpyridin-2-aMine
• CAS NO: 1037253-14-7
• Molecular Formula: C7H9BrN2
• Molecular Weight: 201.06376
• Mol File: 1037253-14-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-broMo-3-ethylpyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMo-3-ethylpyridin-2-aMine(1037253-14-7)
• EPA Substance Registry System: 5-broMo-3-ethylpyridin-2-aMine(1037253-14-7)

Safety Data

• Hazardous Substances Data: 1037253-14-7(Hazardous Substances Data)

Upstream product

• 138343-75-6 tert-butyl (3-methylpyridin-2-yl)carbamate 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 149489-03-2 tert-butyl (3-ethylpyridin-2-yl)carbamate 
• 42753-67-3 2-amino-3-ethylpyridine 

Relevant articles and documents

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

SPIROCYCLIC ROR-GAMMA MODULATORS

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

BICYCLIC ROR-GAMMA MODULATORS

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Novel Heterocyclic Compounds and Uses Thereof

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS

The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a halogen atom, a lower